BELEODAQ (belinostat)

OFFICE ADMINISTRATION

Indications for Prior Authorization:

  • Indicated for second line therapy for patients with relapsed or refractory peripheral T-cell lymphoma

Patient must meet the following criteria for the above indications:

  • Patients must have failed first line therapy with CHOP or CHOP-like regimens

The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee:

  • For any indications not mentioned above

Dosing:

  • Days 1 to 5 of a 21 day cycle: 1 g/m2 given once daily as an IV infusion over 30 minutes
  • May be repeated until disease progression or unacceptable toxicity

Approval:

6 months


 

Last review date: September 1, 2014

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone